PLSCR1 and COVID-19: Notably, PLSCR1 was shown to impede the entry of multiple SARS-CoV-2 variants, including Alpha, Beta, Gamma, Delta, and Omicron, underscoring its potential as a broad-spectrum therapeutic target for COVID-19 and future coronavirus outbreaks.